rilpivirine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| antivirals Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTI) | 4174 | 500287-72-9 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
A diarylpyrimidine derivative and REVERSE TRANSCRIPTASE INHIBITOR with antiviral activity against HIV-1 that is used in the treatment of HIV INFECTIONS. It is also used in combination with other ANTI-HIV AGENTS, since ANTIVIRAL DRUG RESISTANCE emerges rapidly when it is used alone.
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
| Dose | Unit | Route |
|---|---|---|
| 25 | mg | O |
| 15 | mg | P |
ADMET properties:
| Property | Value | Reference |
|---|---|---|
| BDDCS (Biopharmaceutical Drug Disposition Classification System) | 2 | Hosey CM, Chan R, Benet LZ |
| S (Water solubility) | 0.00 mg/mL | Bocci G, Oprea TI, Benet LZ |
| fu (Fraction unbound in plasma) | 0.00 % | Kawashima H, Watanabe R, Esaki T, Kuroda M, Nagao C, Natsume-Kitatani Y, Ohashi R, Komura H, Mizuguchi K |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| May 20, 2011 | FDA | JANSSEN PRODS | |
| May 18, 2012 | PMDA | JANSSEN PHARMACEUTICAL K.K. |
FDA Adverse Event Reporting System (Female)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Viral load increased | 327.32 | 39.25 | 52 | 1607 | 1322 | 63486041 |
| Viral mutation identified | 196.65 | 39.25 | 35 | 1624 | 1775 | 63485588 |
| Virologic failure | 189.08 | 39.25 | 34 | 1625 | 1828 | 63485535 |
| Blood HIV RNA increased | 147.20 | 39.25 | 24 | 1635 | 715 | 63486648 |
| Exposure during pregnancy | 140.43 | 39.25 | 72 | 1587 | 155475 | 63331888 |
| Injection site nodule | 118.83 | 39.25 | 26 | 1633 | 3809 | 63483554 |
| Drug resistance | 112.42 | 39.25 | 36 | 1623 | 22897 | 63464466 |
| Pathogen resistance | 85.67 | 39.25 | 22 | 1637 | 6376 | 63480987 |
| Abortion spontaneous | 80.33 | 39.25 | 34 | 1625 | 47161 | 63440202 |
| Injection site pain | 67.53 | 39.25 | 42 | 1617 | 129758 | 63357605 |
| Product use in unapproved therapeutic environment | 51.83 | 39.25 | 6 | 1653 | 9 | 63487354 |
| Mycoplasma genitalium infection | 49.01 | 39.25 | 6 | 1653 | 18 | 63487345 |
FDA Adverse Event Reporting System (Male)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Viral load increased | 612.52 | 28.07 | 118 | 3291 | 2409 | 34951113 |
| Virologic failure | 256.57 | 28.07 | 61 | 3348 | 3419 | 34950103 |
| Blood HIV RNA increased | 158.29 | 28.07 | 34 | 3375 | 1196 | 34952326 |
| Injection site pain | 147.19 | 28.07 | 73 | 3336 | 38932 | 34914590 |
| Viral mutation identified | 128.67 | 28.07 | 34 | 3375 | 2920 | 34950602 |
| Product use in unapproved therapeutic environment | 121.71 | 28.07 | 17 | 3392 | 33 | 34953489 |
| Pathogen resistance | 100.62 | 28.07 | 37 | 3372 | 9445 | 34944077 |
| Product dose omission issue | 100.26 | 28.07 | 87 | 3322 | 119624 | 34833898 |
| Product complaint | 85.42 | 28.07 | 29 | 3380 | 5861 | 34947661 |
| Injection site nodule | 76.28 | 28.07 | 20 | 3389 | 1663 | 34951859 |
| Pyelocaliectasis | 58.85 | 28.07 | 15 | 3394 | 1115 | 34952407 |
| Syphilis | 50.17 | 28.07 | 11 | 3398 | 425 | 34953097 |
| Wrong technique in device usage process | 40.96 | 28.07 | 12 | 3397 | 1500 | 34952022 |
| CD4 lymphocytes decreased | 39.29 | 28.07 | 12 | 3397 | 1729 | 34951793 |
| Blood triglycerides abnormal | 37.98 | 28.07 | 8 | 3401 | 255 | 34953267 |
| Drug resistance | 34.89 | 28.07 | 25 | 3384 | 25902 | 34927620 |
| Congenital hydronephrosis | 34.60 | 28.07 | 9 | 3400 | 724 | 34952798 |
| Glomerular filtration rate decreased | 33.80 | 28.07 | 19 | 3390 | 12942 | 34940580 |
| Foetal exposure during pregnancy | 30.34 | 28.07 | 27 | 3382 | 38074 | 34915448 |
| Blood HIV RNA below assay limit | 30.17 | 28.07 | 4 | 3405 | 4 | 34953518 |
FDA Adverse Event Reporting System (Geriatric)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Viral load increased | 411.43 | 24.80 | 77 | 3631 | 2871 | 79737809 |
| Viral mutation identified | 215.19 | 24.80 | 47 | 3661 | 3811 | 79736869 |
| Virologic failure | 211.31 | 24.80 | 47 | 3661 | 4144 | 79736536 |
| Blood HIV RNA increased | 182.41 | 24.80 | 36 | 3672 | 1772 | 79738908 |
| Drug resistance | 130.66 | 24.80 | 55 | 3653 | 42158 | 79698522 |
| Pathogen resistance | 108.43 | 24.80 | 36 | 3672 | 14306 | 79726374 |
| Product dose omission issue | 95.18 | 24.80 | 84 | 3624 | 247453 | 79493227 |
| Drug interaction | 86.35 | 24.80 | 101 | 3607 | 415082 | 79325598 |
| Product use in unapproved therapeutic environment | 69.10 | 24.80 | 9 | 3699 | 24 | 79740656 |
| Exposure during pregnancy | 59.30 | 24.80 | 44 | 3664 | 101088 | 79639592 |
| Product complaint | 57.18 | 24.80 | 22 | 3686 | 13327 | 79727353 |
| Injection site pain | 55.72 | 24.80 | 47 | 3661 | 129791 | 79610889 |
| Abortion spontaneous | 51.94 | 24.80 | 26 | 3682 | 29481 | 79711199 |
| Mycoplasma genitalium infection | 45.55 | 24.80 | 6 | 3702 | 18 | 79740662 |
| Injection site nodule | 43.14 | 24.80 | 13 | 3695 | 3767 | 79736913 |
| Blood triglycerides abnormal | 38.87 | 24.80 | 8 | 3700 | 485 | 79740195 |
| Syphilis | 37.94 | 24.80 | 8 | 3700 | 546 | 79740134 |
| Exposure via skin contact | 35.90 | 24.80 | 7 | 3701 | 322 | 79740358 |
| Gene mutation | 33.97 | 24.80 | 10 | 3698 | 2676 | 79738004 |
| Blood HIV RNA below assay limit | 33.13 | 24.80 | 4 | 3704 | 4 | 79740676 |
| Depressed mood | 30.43 | 24.80 | 22 | 3686 | 48458 | 79692222 |
| Hepatitis C | 28.59 | 24.80 | 13 | 3695 | 11912 | 79728768 |
| Melanoderma | 28.53 | 24.80 | 6 | 3702 | 404 | 79740276 |
| Facial paresis | 26.88 | 24.80 | 10 | 3698 | 5516 | 79735164 |
| Glomerular filtration rate decreased | 25.89 | 24.80 | 15 | 3693 | 22687 | 79717993 |
| Haemorrhoids thrombosed | 25.28 | 24.80 | 5 | 3703 | 248 | 79740432 |
| Ophthalmic herpes simplex | 25.09 | 24.80 | 6 | 3702 | 724 | 79739956 |
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | J05AG05 | ANTIINFECTIVES FOR SYSTEMIC USE ANTIVIRALS FOR SYSTEMIC USE DIRECT ACTING ANTIVIRALS Non-nucleoside reverse transcriptase inhibitors |
| ATC | J05AR08 | ANTIINFECTIVES FOR SYSTEMIC USE ANTIVIRALS FOR SYSTEMIC USE DIRECT ACTING ANTIVIRALS Antivirals for treatment of HIV infections, combinations |
| ATC | J05AR19 | ANTIINFECTIVES FOR SYSTEMIC USE ANTIVIRALS FOR SYSTEMIC USE DIRECT ACTING ANTIVIRALS Antivirals for treatment of HIV infections, combinations |
| ATC | J05AR21 | ANTIINFECTIVES FOR SYSTEMIC USE ANTIVIRALS FOR SYSTEMIC USE DIRECT ACTING ANTIVIRALS Antivirals for treatment of HIV infections, combinations |
| FDA MoA | N0000009948 | Non-Nucleoside Reverse Transcriptase Inhibitors |
| FDA EXT | N0000175460 | Non-Nucleoside Analog |
| FDA EPC | N0000175463 | Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor |
| MeSH PA | D019380 | Anti-HIV Agents |
| MeSH PA | D000890 | Anti-Infective Agents |
| MeSH PA | D044966 | Anti-Retroviral Agents |
| MeSH PA | D000998 | Antiviral Agents |
| MeSH PA | D004791 | Enzyme Inhibitors |
| MeSH PA | D019384 | Nucleic Acid Synthesis Inhibitors |
| MeSH PA | D018894 | Reverse Transcriptase Inhibitors |
| CHEBI has role | CHEBI:50266 | Prodrugs |
| CHEBI has role | CHEBI:53756 | reverse transcriptase inhibitors |
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Human immunodeficiency virus infection | indication | 86406008 | DOID:526 |
| Osteomalacia | contraindication | 4598005 | DOID:10573 |
| Hypophosphatemia | contraindication | 4996001 | |
| Suicidal thoughts | contraindication | 6471006 | |
| Torsades de pointes | contraindication | 31722008 | |
| Fanconi syndrome | contraindication | 40488004 | DOID:1062 |
| Acute nephropathy | contraindication | 58574008 | |
| Hepatic failure | contraindication | 59927004 | |
| Chronic type B viral hepatitis | contraindication | 61977001 | |
| Kidney disease | contraindication | 90708001 | DOID:557 |
| Lactic acidosis | contraindication | 91273001 | DOID:3650 |
| Prolonged QT interval | contraindication | 111975006 | |
| Liver function tests abnormal | contraindication | 166603001 | |
| Steatosis of liver | contraindication | 197321007 | |
| Disease of liver | contraindication | 235856003 | DOID:409 |
| Pathological fracture | contraindication | 268029009 | |
| Severe depression | contraindication | 310497006 | |
| Osteopenia | contraindication | 312894000 | |
| Breastfeeding (mother) | contraindication | 413712001 | |
| Obesity | contraindication | 414916001 | DOID:9970 |
| Congenital long QT syndrome | contraindication | 442917000 |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 5.48 | Basic |
Orange Book patent data (new drug applications)
| Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Patent number | Patent expiration date | Patent use |
|---|---|---|---|---|---|---|---|---|---|---|
| 200MG;EQ 25MG BASE;300MG | COMPLERA | GILEAD SCIENCES INC | N202123 | Aug. 10, 2011 | RX | TABLET | ORAL | 8592397 | Jan. 13, 2024 | TREATMENT OF HIV INFECTION |
| 200MG;EQ 25MG BASE;300MG | COMPLERA | GILEAD SCIENCES INC | N202123 | Aug. 10, 2011 | RX | TABLET | ORAL | 8716264 | Jan. 13, 2024 | TREATMENT OF HIV INFECTION |
| 200MG;EQ 25MG BASE;300MG | COMPLERA | GILEAD SCIENCES INC | N202123 | Aug. 10, 2011 | RX | TABLET | ORAL | 9457036 | Jan. 13, 2024 | TREATMENT OF HIV INFECTION |
| 200MG;EQ 25MG BASE;300MG | COMPLERA | GILEAD SCIENCES INC | N202123 | Aug. 10, 2011 | RX | TABLET | ORAL | 9744181 | Jan. 13, 2024 | TREATMENT OF HIV INFECTION |
| EQ 25MG BASE | EDURANT | JANSSEN PRODS | N202022 | May 20, 2011 | RX | TABLET | ORAL | 7125879 | April 21, 2025 | IN COMBINATION WITH OTHER ANTIRETROVIRAL AGENTS FOR THE TREATMENT OF HIV-1 INFECTION IN TREATMENT-NAIVE ADULT PATIENTS WITH HIV-1 RNA LESS THAN OR EQUAL TO 100,000 AT THE START OF THERAPY |
| EQ 25MG BASE | EDURANT | JANSSEN PRODS | N202022 | May 20, 2011 | RX | TABLET | ORAL | 7125879 | April 21, 2025 | IN COMBINATION WITH OTHER ANTIRETROVIRAL AGENTS FOR THE TREATMENT OF HIV-1 INFECTION IN TREATMENT-NAIVE PATIENTS WITH HIV-1 RNA LESS THAN OR EQUAL TO 100,000 AT THE START OF THERAPY |
| EQ 25MG BASE | EDURANT | JANSSEN PRODS | N202022 | May 20, 2011 | RX | TABLET | ORAL | 7125879 | April 21, 2025 | IN COMBINATION WITH OTHER ANTIRETROVIRAL AGENTS, IS INDICATED FOR THE TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 (HIV-1) INFECTION IN ANTIRETROVIRAL TREATMENT-NAIVE ADULT PATIENTS, AS SET FORTH IN THE LABELING, INCLUDING I&U SECTION |
| EQ 25MG BASE | EDURANT | JANSSEN PRODS | N202022 | May 20, 2011 | RX | TABLET | ORAL | 7125879 | April 21, 2025 | TREATMENT IN COMBINATION WITH CABOTEGRAVIR OF HIV-1 INFECTION IN ADULTS AND ADOLESCENTS 12 AND OLDER TO REPLACE CURRENT REGIMEN IN THOSE WHO ARE VIROLOGICALLY SUPPRESSED ON A STABLE ANTIRETROVIRAL REGIMEN WITH NO HISTORY OF TREATMENT FAILURE |
| 200MG;EQ 25MG BASE;300MG | COMPLERA | GILEAD SCIENCES INC | N202123 | Aug. 10, 2011 | RX | TABLET | ORAL | 7125879 | April 21, 2025 | TREATMENT OF HIV INFECTION |
| 200MG;EQ 25MG BASE;EQ 25MG BASE | ODEFSEY | GILEAD SCIENCES INC | N208351 | March 1, 2016 | RX | TABLET | ORAL | 7125879 | April 21, 2025 | TREATMENT OF HIV INFECTION |
| EQ 50MG BASE;EQ 25MG BASE | JULUCA | VIIV HLTHCARE | N210192 | Nov. 21, 2017 | RX | TABLET | ORAL | 7125879 | April 21, 2025 | TREATMENT OF HIV INFECTION |
| 400MG/2ML (200MG/ML);600MG/2ML (300MG/ML) | CABENUVA KIT | VIIV HLTHCARE | N212888 | Jan. 21, 2021 | RX | SUSPENSION, EXTENDED RELEASE | INTRAMUSCULAR | 7125879 | April 21, 2025 | TREATMENT OF HIV-1 INFECTION IN ADULTS AND ADOLESCENTS 12 YEARS OF AGE AND OLDER AND WEIGHING AT LEAST 35 KG |
| 600MG/3ML (200MG/ML);900MG/3ML (300MG/ML) | CABENUVA KIT | VIIV HLTHCARE | N212888 | Jan. 21, 2021 | RX | SUSPENSION, EXTENDED RELEASE | INTRAMUSCULAR | 7125879 | April 21, 2025 | TREATMENT OF HIV-1 INFECTION IN ADULTS AND ADOLESCENTS 12 YEARS OF AGE AND OLDER AND WEIGHING AT LEAST 35 KG |
| 200MG;EQ 25MG BASE;300MG | COMPLERA | GILEAD SCIENCES INC | N202123 | Aug. 10, 2011 | RX | TABLET | ORAL | 8841310 | Dec. 9, 2025 | TREATMENT OF HIV INFECTION |
| 400MG/2ML (200MG/ML);600MG/2ML (300MG/ML) | CABENUVA KIT | VIIV HLTHCARE | N212888 | Jan. 21, 2021 | RX | SUSPENSION, EXTENDED RELEASE | INTRAMUSCULAR | 8410103 | April 28, 2026 | TREATMENT OF HIV-1 INFECTION IN ADULTS AND ADOLESCENTS 12 YEARS OF AGE AND OLDER AND WEIGHING AT LEAST 35 KG |
| 600MG/3ML (200MG/ML);900MG/3ML (300MG/ML) | CABENUVA KIT | VIIV HLTHCARE | N212888 | Jan. 21, 2021 | RX | SUSPENSION, EXTENDED RELEASE | INTRAMUSCULAR | 8410103 | April 28, 2026 | TREATMENT OF HIV-1 INFECTION IN ADULTS AND ADOLESCENTS 12 YEARS OF AGE AND OLDER AND WEIGHING AT LEAST 35 KG |
| 400MG/2ML (200MG/ML);600MG/2ML (300MG/ML) | CABENUVA KIT | VIIV HLTHCARE | N212888 | Jan. 21, 2021 | RX | SUSPENSION, EXTENDED RELEASE | INTRAMUSCULAR | 11389447 | June 30, 2027 | TREATMENT OF HIV-1 INFECTION IN ADULTS AND ADOLESCENTS 12 YEARS OF AGE AND OLDER AND WEIGHING AT LEAST 35 KG BY MONTHLY ADMINISTRATION OF RILPIVIRINE SUSPENSION AS PART OF COMBINATION THERAPY |
| 600MG/3ML (200MG/ML);900MG/3ML (300MG/ML) | CABENUVA KIT | VIIV HLTHCARE | N212888 | Jan. 21, 2021 | RX | SUSPENSION, EXTENDED RELEASE | INTRAMUSCULAR | 11389447 | June 30, 2027 | TREATMENT OF HIV-1 INFECTION IN ADULTS AND ADOLESCENTS 12 YEARS OF AGE AND OLDER AND WEIGHING AT LEAST 35 KG BY MONTHLY ADMINISTRATION OF RILPIVIRINE SUSPENSION AS PART OF COMBINATION THERAPY |
| EQ 50MG BASE;EQ 25MG BASE | JULUCA | VIIV HLTHCARE | N210192 | Nov. 21, 2017 | RX | TABLET | ORAL | 10426780 | Jan. 24, 2031 | TREATMENT OF HIV INFECTION |
| 400MG/2ML (200MG/ML);600MG/2ML (300MG/ML) | CABENUVA KIT | VIIV HLTHCARE | N212888 | Jan. 21, 2021 | RX | SUSPENSION, EXTENDED RELEASE | INTRAMUSCULAR | 11224597 | Sept. 15, 2031 | TREATMENT OF HIV-1 INFECTION IN ADULTS AND ADOLESCENTS 12 YEARS OF AGE AND OLDER AND WEIGHING AT LEAST 35 KG |
| 600MG/3ML (200MG/ML);900MG/3ML (300MG/ML) | CABENUVA KIT | VIIV HLTHCARE | N212888 | Jan. 21, 2021 | RX | SUSPENSION, EXTENDED RELEASE | INTRAMUSCULAR | 11224597 | Sept. 15, 2031 | TREATMENT OF HIV-1 INFECTION IN ADULTS AND ADOLESCENTS 12 YEARS OF AGE AND OLDER AND WEIGHING AT LEAST 35 KG |
| 200MG;EQ 25MG BASE;EQ 25MG BASE | ODEFSEY | GILEAD SCIENCES INC | N208351 | March 1, 2016 | RX | TABLET | ORAL | 8754065 | Aug. 15, 2032 | TREATMENT OF HIV INFECTION |
| 200MG;EQ 25MG BASE;EQ 25MG BASE | ODEFSEY | GILEAD SCIENCES INC | N208351 | March 1, 2016 | RX | TABLET | ORAL | 9296769 | Aug. 15, 2032 | TREATMENT OF HIV INFECTION |
Orange Book exclusivity data (new drug applications)
| Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Exclusivity date | Description |
|---|---|---|---|---|---|---|---|---|---|
| 400MG/2ML (200MG/ML);600MG/2ML (300MG/ML) | CABENUVA KIT | VIIV HLTHCARE | N212888 | Jan. 21, 2021 | RX | SUSPENSION, EXTENDED RELEASE | INTRAMUSCULAR | Jan. 31, 2025 | NEW DOSING SCHEDULE FOR CABOTEGRAVIR/RILPIVRINE INJECTION EVERY 2 MONTHS |
| 600MG/3ML (200MG/ML);900MG/3ML (300MG/ML) | CABENUVA KIT | VIIV HLTHCARE | N212888 | Jan. 21, 2021 | RX | SUSPENSION, EXTENDED RELEASE | INTRAMUSCULAR | Jan. 31, 2025 | NEW DOSING SCHEDULE FOR CABOTEGRAVIR/RILPIVRINE INJECTION EVERY 2 MONTHS |
| 400MG/2ML (200MG/ML);600MG/2ML (300MG/ML) | CABENUVA KIT | VIIV HLTHCARE | N212888 | Jan. 21, 2021 | RX | SUSPENSION, EXTENDED RELEASE | INTRAMUSCULAR | March 29, 2025 | NEW PATIENT POPULATION |
| 600MG/3ML (200MG/ML);900MG/3ML (300MG/ML) | CABENUVA KIT | VIIV HLTHCARE | N212888 | Jan. 21, 2021 | RX | SUSPENSION, EXTENDED RELEASE | INTRAMUSCULAR | March 29, 2025 | NEW PATIENT POPULATION |
| 400MG/2ML (200MG/ML);600MG/2ML (300MG/ML) | CABENUVA KIT | VIIV HLTHCARE | N212888 | Jan. 21, 2021 | RX | SUSPENSION, EXTENDED RELEASE | INTRAMUSCULAR | Jan. 21, 2026 | NEW CHEMICAL ENTITY |
| 600MG/3ML (200MG/ML);900MG/3ML (300MG/ML) | CABENUVA KIT | VIIV HLTHCARE | N212888 | Jan. 21, 2021 | RX | SUSPENSION, EXTENDED RELEASE | INTRAMUSCULAR | Jan. 21, 2026 | NEW CHEMICAL ENTITY |
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Potassium voltage-gated channel subfamily H member 2 | Ion channel | IC50 | 6.30 | CHEMBL | |||||
| ATP-binding cassette sub-family G member 2 | Transporter | IC50 | 5.82 | CHEMBL | |||||
| Cytochrome P450 1A2 | Enzyme | IC50 | 5.04 | CHEMBL | |||||
| Reverse transcriptase/RNaseH | Enzyme | INHIBITOR | IC50 | 9.17 | CHEMBL | CHEMBL | |||
| Reverse transcriptase | Enzyme | IC50 | 7.82 | CHEMBL | |||||
| Reverse transcriptase protein | Unclassified | EC50 | 9.10 | CHEMBL |
External reference:
| ID | Source |
|---|---|
| 4030730 | VUID |
| N0000182740 | NUI |
| D09720 | KEGG_DRUG |
| 700361-47-3 | SECONDARY_CAS_RN |
| 4030730 | VANDF |
| 4030731 | VANDF |
| C1566826 | UMLSCUI |
| CHEBI:68606 | CHEBI |
| T27 | PDB_CHEM_ID |
| CHEMBL175691 | ChEMBL_ID |
| CHEMBL1628504 | ChEMBL_ID |
| D000068696 | MESH_DESCRIPTOR_UI |
| DB08864 | DRUGBANK_ID |
| 11387 | IUPHAR_LIGAND_ID |
| 8469 | INN_ID |
| FI96A8X663 | UNII |
| 6451164 | PUBCHEM_CID |
| 1102270 | RXNORM |
| 181475 | MMSL |
| 27887 | MMSL |
| 31577 | MMSL |
| d07776 | MMSL |
| 013795 | NDDF |
| 013796 | NDDF |
| 703123005 | SNOMEDCT_US |
| 703124004 | SNOMEDCT_US |
| 703777002 | SNOMEDCT_US |
Pharmaceutical products:
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| Juluca | HUMAN PRESCRIPTION DRUG LABEL | 2 | 49702-242 | TABLET, FILM COATED | 25 mg | ORAL | NDA | 28 sections |
| Juluca | HUMAN PRESCRIPTION DRUG LABEL | 2 | 49702-242 | TABLET, FILM COATED | 25 mg | ORAL | NDA | 28 sections |
| Juluca | HUMAN PRESCRIPTION DRUG LABEL | 2 | 49702-242 | TABLET, FILM COATED | 25 mg | ORAL | NDA | 28 sections |
| Juluca | HUMAN PRESCRIPTION DRUG LABEL | 2 | 49702-242 | TABLET, FILM COATED | 25 mg | ORAL | NDA | 28 sections |
| COMPLERA | HUMAN PRESCRIPTION DRUG LABEL | 3 | 54868-6360 | TABLET, FILM COATED | 25 mg | ORAL | NDA | 32 sections |
| EDURANT | HUMAN PRESCRIPTION DRUG LABEL | 1 | 59676-278 | TABLET, FILM COATED | 25 mg | ORAL | NDA | 29 sections |
| EDURANT | HUMAN PRESCRIPTION DRUG LABEL | 1 | 59676-278 | TABLET, FILM COATED | 25 mg | ORAL | NDA | 29 sections |
| EDURANT | HUMAN PRESCRIPTION DRUG LABEL | 1 | 59676-278 | TABLET, FILM COATED | 25 mg | ORAL | NDA | 29 sections |
| COMPLERA | HUMAN PRESCRIPTION DRUG LABEL | 3 | 61958-1101 | TABLET, FILM COATED | 25 mg | ORAL | NDA | 31 sections |
| COMPLERA Access | HUMAN PRESCRIPTION DRUG LABEL | 3 | 61958-1102 | TABLET, FILM COATED | 25 mg | ORAL | EXPORT ONLY | 33 sections |
| ODEFSEY | HUMAN PRESCRIPTION DRUG LABEL | 3 | 61958-2101 | TABLET | 25 mg | ORAL | NDA | 35 sections |
| ODEFSEY | HUMAN PRESCRIPTION DRUG LABEL | 3 | 61958-2101 | TABLET | 25 mg | ORAL | NDA | 35 sections |
| COMPLERA | HUMAN PRESCRIPTION DRUG LABEL | 3 | 70518-0677 | TABLET, FILM COATED | 25 mg | ORAL | NDA | 30 sections |